The expanded Centre for Clinical Haematology (CCH) at the Queen Elizabeth Hospital in Birmingham said it has seen a “significant impact” in the 12 months since its launch.
Funded by the Greater Birmingham & Solihull Local Enterprise Partnership (GBSLEP), Cure Leukaemia and University Hospitals Birmingham NHS Foundation Trust (UHB), the centre underwent a £3.4m expansion on 8 January 2018. The centre was officially opened by HRH The Earl of Wessex in June 2018.
Since the redevelopment, the centre has housed two pioneering blood cancer trials and also led the development of four new clinical trials of novel drug and transplant therapies.
It has also provided access to more than £10m in free drugs for clinical trial patients and gained £6m investment from the global pharmaceutical sector. Some 25 new jobs have also been created in the life science sector.
Furthermore, its patient treatments increased from 10,000 to 19,000 and it treated 9,612 patients over the year.
Cure Leukaemia CEO James McLaughlin said: “It is fantastic to see the progress that has already been made since the CCH reopened and everyone associated with the charity is very proud to have played a major role in making this possible. It is vital that we continue to support the clinical teams that operate within the CCH and we are constantly striving to find new ways to fund the growth and innovation that is possible as a result of the centre.”
Clinical service lead for Haematology at the CCH, Dr Fiona Clark added: “The expanded centre has been transformational already but we see this as just the start. We have seen the benefits of having clinicians, research nurses, therapy nurses and research teams all under one roof and this has been the catalyst for a vastly improved patient pathway and experience.
“The increased capacity will allow further innovation and improvement in the care we can provide and we have recently been accredited to deliver groundbreaking CAR T-Cell immunotherapy therapy to patients, in part because of the excellent facilities and apheresis department housed in the CCH.”